KEAP1 and hepatocellular carcinoma: For example, luteolin has been shown to inhibit the Keap1/Nrf2 signaling pathway in human hepatoma (HepG2), rat liver epithelial (RL-34), and mouse hepatoma (Hepa1c1c7) cells treated with dioxin (TCDD) (Zhang et al., 2014).